Analyses Still PositiveIn spite of market volatility and the ongoing wait for FDA news regarding AcuVid, the metrics for THRM remain positive. With a Fair Value sp by Morningstar of $.45 the road to $.50 on a final FDA submission seems relatively clear. Exceeding overbought and overvalued territory which currently sits just below $1.00 should be easily met with an FDA EUA.
Like everyone else it would be nice to see an update on Venowave as anything positive on this front could cushion the current direction of the sp while investors wait for more news on AcuVid.
GLTE!!!